Blocking Immune Cell Entry Preserves Brain Tissue in Alzheimer’s Mouse Study
In mice with Alzheimer’s-like tau buildup, an antibody that limited T cell entry into the brain helped retain about 40% more tissue in memory-related regions than in untreated animals, even though tau levels were similar. The work suggests that targeting the brain’s immune response to tau, rather than clearing tau tangles directly, may help protect neurons. Published in Neuron, the findings point toward a possible strategy for tauopathies, including Alzheimer’s disease.
Tauopathies involve tau clumping; Alzheimer's also has amyloid. Two approved antibodies, lecanemab and donanemab, clear amyloid and modestly slow decline, but haven't been shown to stop neuron death or help primary tauopathies.
Earlier work from the same lab found that T cells infiltrate the brains of tau-burdened mice, gathering where tau was heaviest and driving degeneration; a related September paper traced their activation to lymph nodes outside the brain. The new study targets the CXCL10 signal and its CXCR3 receptor.
If the approach holds up beyond mice, it could matter most to people with primary tauopathies, who currently have no disease-modifying option, and to Alzheimer's patients whose amyloid-targeting drugs don't halt neuron loss. Families and caregivers, who absorb the long-term costs of decline, may benefit from any treatment that preserves memory-related tissue. Still, this is early animal work; whether blocking T cell entry helps people, and whether it carries risks from immune suppression, remains unknown.